

RESEARCH ARTICLE

Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease

Maria Victoria Fernández^{1,2}, Jong Hun Kim^{1,2,3}, John P. Budde^{1,2}, Kathleen Black^{1,2}, Alexandra Medvedeva^{1,2}, Ben Saef^{1,2}, Yuetiva Deming^{1,2}, Jorge Del-Aguila^{1,2}, Laura Ibañez^{1,2}, Umber Dube^{1,2,4}, Oscar Harari^{1,2}, Joanne Norton^{1,2}, Rachel Chasse^{1,2}, John C. Morris^{2,5}, Alison Goate⁶, NIA-LOAD family study group[†], NCRAD[†], Carlos Cruchaga^{1,2*}

1 Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States of America, **2** Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, United States of America, **3** Department of Neurology, Dementia Center, Ilsan hospital, National Health Insurance Service, Goyang, South Korea, **4** Medical Scientist Training Program, Division of Biology and Biomedical sciences, School of Medicine, Washington University in Saint Louis, St. Louis, MO, United States of America, **5** Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, United States of America, **6** Ronald M. Loeb Center for Alzheimer's disease, Dept of Neuroscience, Icahn School of Medicine at Mount Sinai, ICAHN 10–52, New York, NY, United States of America

^{††} Membership of the NIA-LOAD and NCRAD Family Study Group is provided in the Acknowledgments.
* cruchagac@wustl.edu



OPEN ACCESS

Citation: Fernández MV, Kim JH, Budde JP, Black K, Medvedeva A, Saef B, et al. (2017) Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. *PLoS Genet* 13(11): e1007045. <https://doi.org/10.1371/journal.pgen.1007045>

Editor: Amanda J. Myers, University of Miami, Miller School of Medicine, UNITED STATES

Received: May 4, 2017

Accepted: September 27, 2017

Published: November 1, 2017

Copyright: © 2017 Fernández et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data has been submitted to NIAGADS (<https://www.niagads.org/adsp/content/home>) and the number for this data is NG00060. Data is available to researchers upon request through the dbGaP Authorized Access web page (<https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login>).

Funding: This work was supported by grants from the National Institutes of Health (R01-AG044546, P01-AG003991, and RF1AG053303), the Alzheimer Association (NIRG-11-200110, BAND-14-338165

Abstract

Alzheimer disease (AD), Frontotemporal lobar degeneration (FTD), Amyotrophic lateral sclerosis (ALS) and Parkinson disease (PD) have a certain degree of clinical, pathological and molecular overlap. Previous studies indicate that causative mutations in AD and FTD/ALS genes can be found in clinical familial AD. We examined the presence of causative and low frequency coding variants in the AD, FTD, ALS and PD Mendelian genes, in over 450 families with clinical history of AD and over 11,710 sporadic cases and cognitive normal participants from North America. Known pathogenic mutations were found in 1.05% of the sporadic cases, in 0.69% of the cognitively normal participants and in 4.22% of the families. A trend towards enrichment, albeit non-significant, was observed for most AD, FTD and PD genes. Only *PSEN1* and *PINK1* showed consistent association with AD cases when we used ExAC as the control population. These results suggest that current study designs may contain heterogeneity and contamination of the control population, and that current statistical methods for the discovery of novel genes with real pathogenic variants in complex late onset diseases may be inadequate or underpowered to identify genes carrying pathogenic mutations.

Author summary

In this study we provide further genetic evidence of the clinical, pathological and molecular overlap between neurodegenerative diseases. We screened the known Mendelian

and BFG-15-362540) and the JPB Foundation. The recruitment and clinical characterization of research participants at Washington University were supported by NIH P50-AG05681, P01-AG03991, and P01-AG026276. Samples from the National Cell Repository for Alzheimer's Disease (NCRAD), which receives government support under a cooperative agreement grant (U24-AG21886) awarded by the National Institute on Aging (NIA), were used in this study. NIALOAD samples were collected under a cooperative agreement grant (U24 AG026395) awarded by the National Institute on Aging. Members of the National Institute on Aging Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD NCRAD) Family Study Group include the following: Richard Mayeux, MD, MSc; Martin Farlow, MD; Tatiana Foroud, PhD; Kelley Faber, MS; Bradley F. Boeve, MD; Neill R. Graff-Radford, MD; David A. Bennett, MD; Robert A. Sweet, MD; Roger Rosenberg, MD; Thomas D. Bird, MD; Carlos Cruchaga, PhD; and Jeremy M. Silverman, PhD. The Alzheimer's Disease Sequencing Project (ADSP) is comprised of two Alzheimer's Disease (AD) genetics consortia and three National Human Genome Research Institute (NHGRI) funded Large Scale Sequencing and Analysis Centers (LSAC). The two AD genetics consortia are the Alzheimer's Disease Genetics Consortium (ADGC) funded by NIA (U01 AG032984), and the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) funded by NIA (R01 AG033193), the National Heart, Lung, and Blood Institute (NHLBI), other National Institute of Health (NIH) institutes and other foreign governmental and non-governmental organizations. The Discovery Phase analysis of sequence data is supported through UF1AG047133 (to Drs. Schellenberg, Farrer, Pericak-Vance, Mayeux, and Haines); U01AG049505 to Dr. Seshadri; U01AG049506 to Dr. Boerwinkle; U01AG049507 to Dr. Wijsman; and U01AG049508 to Dr. Goate and the Discovery Extension Phase analysis is supported through U01AG052411 to Dr. Goate and U01AG052410 to Dr. Pericak-Vance. Data generation and harmonization in the Follow-up Phases is supported by U54AG052427 (to Drs. Schellenberg and Wang). The ADGC cohorts include: Adult Changes in Thought (ACT), the Alzheimer's Disease Centers (ADC), the Chicago Health and Aging Project (CHAP), the Memory and Aging Project (MAP), Mayo Clinic (MAYO), Mayo Parkinson's Disease controls, University of Miami, the Multi-Institutional Research in Alzheimer's Genetic Epidemiology Study (MIRAGE), the National Cell Repository for Alzheimer's Disease (NCRAD), the National Institute on Aging Late

genes in Alzheimer disease (AD), Frontotemporal Dementia (FTD), Parkinson disease (PD) and Amyotrophic Lateral Sclerosis (ALS) disease in over 13,292 individuals. We report the presence of known pathogenic mutations in AD, FTD and PD genes in both sporadic and familial late onset AD cases and even cognitively normal individuals, pointing to contamination of control cohorts with asymptomatic cases. We also observed an enrichment, although not statistically significant, in most of AD, FTD and PD genes, reinforcing the idea of pathologic crossover among these diseases. However, the fact that genes carrying known pathogenic mutation do not show significant association calls for a reevaluation of current statistical methods.

Introduction

Neurodegenerative diseases like Alzheimer Disease (AD), Frontotemporal dementia (FTD), Parkinson disease (PD) and Amyotrophic Lateral Sclerosis (ALS) share clinical and pathologic features. Dementia is characteristic of AD and FTD, but may also present in PD and ALS [1]. In all these diseases we can observe two types of manifestations, either a rare and following Mendelian inheritance, or a more common seemingly non-familial representation [2]. All these diseases share the pathologic hallmark of presenting protein aggregates in different areas of the central nervous system. The rare familial forms have been key to our understanding of each disease's pathology; these are well characterized by a dominant pathologic protein aggregate in a specific location within the nervous system caused by the impairment of a specific set of genes [2]. However, a clinical, and pathological crossover has been observed in the idiopathic forms [3] allowing for the assumption that different types of dementia may have overlapping genetic causes.

AD is the most common neurodegenerative disease affecting over 5.5 million Americans [4]. AD's main pathologic hallmark is the extracellular deposit of β -amyloid plaques, followed by the presence of intracellular aggregates of neurofibrillary tangles of phosphorylated tau protein (*MAPT*). Pathogenic variants in *APP*, *PSEN1* and *PSEN2* were thought to exclusively cause early onset familial AD (EOFAD) [5], but the screening of some late onset families and even sporadic cases, revealed that the contribution of familial genetic variants in *APP*, *PSEN1* and *PSEN2* in idiopathic cases cannot be neglected [6–8].

Intracellular aggregates of hyperphosphorylated tau (encoded by *MAPT*) is the second neuropathological hallmark of AD. Tau aggregates also characterize a subgroup of FTD cases (FTD-Tau) in which genetic linkage to *MAPT* was found [9]. The discovery of the gene involved in tau deposits stimulated a series of studies seeking association between polymorphisms within *MAPT* and AD. Preliminary studies investigating the genetic relationship between *MAPT* and AD produced contradictory results [10,11] although the latest reports provide more compelling evidence that common variants in the *MAPT* region confer risk for AD, particularly in cases who are non-carriers of the APOE ϵ 4 allele [11–15]. Other familial FTD cases that are negative for tau protein aggregates present ubiquitin immunoreactivity (FTD-U), which was initially associated with genetic variants in *GRN* [16]. Together with *MAPT*, *GRN* genetic variants cause up to 50% of familial FTD cases, but *GRN* genetic variants have also been regarded as risk factors for AD [17–20]. Other familial genes later associated with FTD-U subtypes are *C9ORF72*, *TARDBP*, *VCP*, *CHMP2B*, *UBQLN2* and *FUS* [21]. A hexanucleotide repeat expansion in *C9ORF72* was identified as major risk factor for FTD [22,23] although its pathogenicity towards ubiquitin reactive deposits is not well understood. *C9ORF72* is also the most common risk factor for familial ALS [24,25] and multiple studies

Onset Alzheimer's Disease Family Study (NIA-LOAD), the Religious Orders Study (ROS), the Texas Alzheimer's Research and Care Consortium (TARC), Vanderbilt University/Case Western Reserve University (VAN/CWRU), the Washington Heights-Inwood Columbia Aging Project (WHICAP) and the Washington University Sequencing Project (WUSP), the Columbia University Hispanic-Estudio Familiar de Influencia Genetica de Alzheimer (EFIGA), the University of Toronto (UT), and Genetic Differences (GD). The CHARGE cohorts, with funding provided by 5RC2HL102419 and HL105756, include the following: Atherosclerosis Risk in Communities (ARIC) Study which is carried out as a collaborative study supported by NHLBI contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), Austrian Stroke Prevention Study (ASPS), Cardiovascular Health Study (CHS), Erasmus Rucphen Family Study (ERF), Framingham Heart Study (FHS), and Rotterdam Study (RS). CHS research was supported by contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grants U01HL080295 and U01HL130114 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629, R01AG15928, and R01AG20098 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The three LSACs are: the Human Genome Sequencing Center at the Baylor College of Medicine (U54HG003273), the Broad Institute Genome Center (U54HG003067), and the Washington University Genome Institute (U54HG003079). Biological samples and associated phenotypic data used in primary data analyses were stored at Study Investigators institutions, and at the National Cell Repository for Alzheimer's Disease (NCRAD, U24AG021886) at Indiana University funded by NIA. Associated Phenotypic Data used in primary and secondary data analyses were provided by Study Investigators, the NIA funded Alzheimer's Disease Centers (ADCs), and the National Alzheimer's Coordinating Center (NACC, U01AG016976) and the National Institute on Aging Genetics of

have reported clinical AD cases with the full *C9ORF72* expansion [26–29], extending the possible genetic continuum from AD to FTD and ALS. Shared genetic variants between FTD and ALS have been found in *TARDBP*, *VCP*, *UBQLN2* and *FUS* [30–35] but their association with AD has not yet been reported. Other than the shared variants with FTD, the majority of familial ALS is caused by mutations in *SOD1* [36,37]. Recently, mutations in *OPTN*, and *PFN1* have been reported in ALS kindreds [37]. No associations have yet been reported between ALS genes and AD pathology, despite some attempts to demonstrate an association between common *SOD1* variants and AD under the paradigm of a common oxidative stress pathway [38].

Finally, although AD is primarily characterized by cognitive deficits and PD by motor impairment, a clinical and pathological cross-over has been identified in several instances by the presence of dementia in PD patients [39] and motor symptoms in AD patients [40]. Pathologically, tau aggregates can be present to different degrees in sporadic PD [41] and more than 50% of people with AD show α -synuclein aggregates [41]. Lewy bodies, composed of α -synuclein aggregates, the pathological hallmark of PD, are attributed to pathogenic variants in the *SNCA* gene; although genetic variants in *LRRK2*, *PARK2*, *PARK7* and *PINK1* have also been linked to familial PD [42]. Combined meta-analysis of AD and PD GWAS revealed the lack of variants that increase the risk of developing both diseases [43]; although later on, a genetic overlap between AD and PD at the *MAPT* locus was detected [44] and recent studies have detected pathogenic *PARK2* mutations in sporadic early onset AD cases [15].

A genetic overlap among all these neurodegenerative diseases cannot be ignored, and may certainly be underestimated since most of the previous studies performed either two by two gene/disease analysis, which does not cover the full spectrum of genes, or GWAS, which does not cover genetic variants across the frequency spectrum.

In a previous work we reported an enrichment of known pathogenic and novel rare variants in *APP*, *PSEN1*, *PSEN2*, *GRN* and *MAPT* in LOAD families [45]. In this work, we expanded our analysis to a thorough examination of all genes known to cause Mendelian forms of AD, FTD, ALS, and PD. We evaluate the presence of rare and nonsynonymous genetic variants in these 30 genes not only in a large independent familial dataset (467 families), but also in two large sporadic cohorts, 851 in-house sporadic AD cases and controls and in the sporadic ADSP (Alzheimer Disease Sequencing Project) dataset (<https://www.niagads.org/adsp/content/home>, accessed August 2016).

Results

We identified 36 reported pathogenic Mendelian variants in 11 genes (*APP*, *PSEN1*, *PSEN2*, *GRN*, *MAPT*, *TARDBP*, *VCP*, *C9ORF72*, *LRRK2*, *PARK2*, and *PINK1*) across the three datasets examined (Table 1). Fifteen variants were found in 41 subjects (2.6%) from 19 different families; 9 variants across 17 individuals (2.59% of cases and 1.59% of controls) from the Knight-ADRC-NIA-LOAD (KANL) sporadic dataset; and 25 variants across 85 individuals (0.94% of cases and 0.63% of controls) from the ADSP sporadic dataset (Table 1). The prevalence of genetic variants between the sporadic and familial datasets tends to be higher in cases with strong family history compared to the sporadic. In the AD genes 1.56% of the families, 0.94% of the KANL sporadic cases, 0.27% of the KANL sporadic controls, 0.30% of the ADSP sporadic cases and 0.13% of the ADSP sporadic controls carried a previously reported pathogenic variant. It was similar for FTD genes in which 0.88% families, 0.24% of the KANL sporadic cases, 0.24% of the KANL sporadic controls, 0.24% of the ADSP sporadic cases and 0.02% of the ADSP sporadic controls carried a pathogenic variant. The *C9ORF72* mutation is an introic hexanucleotide repeat that cannot be called by WES or WGS; therefore, we could not use the sequence data to call this variant. We genotyped this variant by repeat-primed PCR in a

Alzheimer's Disease Data Storage Site (NIAGADS, U24AG041689) at the University of Pennsylvania, funded by NIA, and at the Database for Genotypes and Phenotypes (dbGaP) funded by NIH. This research was supported in part by the Intramural Research Program of the National Institutes of Health, National Library of Medicine. Contributors to the Genetic Analysis Data included Study Investigators on projects that were individually funded by NIA, and other NIH institutes, and by private U.S. organizations, or foreign governmental or nongovernmental organizations. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

subset of unrelated 819 AD cases and 502 controls from the Knight-ADRC and in 872 unrelated familial AD cases from the NIA-LOAD dataset. We found the repeat expansion in 0.85% of the unrelated cases and 0.57% of the families (10 individuals in total) carry the *C9ORF72* repeat expansion. Interestingly, reported pathogenic mutations in PD genes were found as much or even more frequent than AD mutations, especially within the ADSP dataset. These mutations were found in eight families (1.77%), seven (0.87%) sporadic KANL, and up to 46 (0.42%) individuals from the sporadic ADSP.

In order to evaluate whether there was a differential finding of pathogenic variants between cohorts, KANL and ADSP, we performed Chi-Squared and Fisher statistics. We used the unrelated KANL dataset and the sporadic ADSP to run association and Fisher analysis for the variants in [Table 1](#) using Plink1.9. None of the examined variants showed differential frequency between datasets except for *PARK2* p.(Glu34fs), which was nominally more frequent in the unrelated dataset ([S2 Table](#)). Using the familial dataset, we could evaluate the segregation pattern and penetrance of these variants ([Table 2](#)).

Known AD pathogenic variants

Mutations in Mendelian AD genes are known to be autosomal dominant with complete penetrance; but we found that the variants identified in this study did not always present complete penetrance or segregate perfectly with disease status ([Table 2](#)). First, the pathogenic variant *PSEN1* p.(Ala79Val) [46] was detected in a 67 yrs control from a large family with several affected members and an average AAO around the seventies (Fam #1). Genotyping of the mutation in up to 19 members of the family indicated incomplete penetrance ([Fig 1A](#)), given the presence of phenocopies and some non-affected carriers, possible presymptomatic cases. In addition, this variant was found in seven cases from the ADSP dataset with an average AAO of 68 yrs. The pathogenic variant *PSEN1* p.(Leu85Pro) [47] was detected in a family of four affected and two non-demented individuals (Fam #2), but only one of the affected individuals was a carrier of the genetic variant. The pathogenic variant *PSEN1* p.(Gly206Ala) [48] was found in one case of an AAO 55 yrs, self-reported Caribbean origin (Fam #3). This variant was originally reported in 194 families of Caribbean Hispanic origin [48,49]. We also detected this variant in four cases from the sporadic ADSP dataset, one of European American origin (AAO = 63) and three with Hispanic ethnicity (mean AAO = 70). Variant *PSEN2* p.(Asn141Ile), also pathogenic [51], was detected in one family (Fam #5) and in one sporadic case (AAO = 53) of the KANL cohort. However, after further examination of the clinical history of this participant we detected a reported family history of dementia (Supplementary results). Variant *PSEN2* p.(Met174Val) [52] was detected in two families: Fam #6 was composed of six affected individuals and one diagnosed as non-demented. Only one affected and the cognitively-normal family members were carriers of the variant ([Fig 1B](#)). Similarly, Fam #7 has five affected members and three cognitively normal members, in which only one cognitively normal member (the marry-in) was a carrier of the reported pathogenic variant. This variant was also observed in one control of the KANL sporadic dataset (ALA = 72) and in two cases (mean AAO = 82) and four cognitively normal (64, 63, 84 and 85 yrs ALA) individuals from the sporadic ADSP dataset.

Together these results suggest that previously reported pathogenic variants in Mendelian AD genes may present imperfect segregation, given the existence of phenocopies (Fam #1, Fam #6); and/or incomplete penetrance due to the presence of older cognitive normal carriers that may carry additional modifying factors. Also, their finding within the sporadic cohorts calls for a reexamination of the non-affected carriers as possible presymptomatic individuals.

Known pathogenic variants in these genes were also observed exclusively within the "sporadic" datasets. Two affected individuals of the sporadic KANL cohort with age at onset

Table 1. List of reported* pathogenic variants in genes for Alzheimer disease (AD), Frontotemporal dementia (FTD) and Parkinson disease (PD) detected in the familial cohort, the sporadic KANL cohort and the ADSP sporadic cohort. We provide the number and percentage of families (NF), cases (CA) and controls (CO) that were carriers of each variant.

Disease	GENE	p.CHANGE	Familial KANL & ADSP (450 fams, 1090 CA, 441 CO)			sporadic KANL (424 CA, 377 CO)		sporadic ADSP (5844 CA, 4767 CO)	
			NF (%)	CA N (%)	CO N (%)	CA N (%)	CO N (%)	CA N (%)	CO N (%)
AD	APP	p.(Ile716Val)	-	-	-	2 (0.47)	-	-	-
		p.(Val717Phe)	-	-	-	-	-	1 (0.02)	-
	PSEN1	p.(Ala79Val)	1 (0.22)	4 (0.37)	2 (0.45)	-	-	7 (0.07)	-
		p.(Leu85Pro)	1 (0.22)	1 (0.09)	-	-	-	-	-
		p.(Gly206Ala)	1 (0.22)	1 (0.09)	-	-	-	4 (0.04)	-
		p.(His214Tyr)	-	-	-	-	-	1 (0.02)	-
		p.(Leu226Arg)	-	-	-	1 (0.24)	-	-	-
		p.(Arg269Gly)	1 (0.22)	1 (0.09)	-	-	-	-	-
		p.(Ala409Thr)	-	-	-	-	-	-	1 (0.02)
	PSEN2	p.(Val412Ile)	-	-	-	-	-	1 (0.02)	-
		p.(Ala85Val)	-	-	-	-	-	-	1 (0.02)
		p.(Asn141Ile)	1 (0.22)	1 (0.09)	-	1 (0.24)	-	-	-
		p.(Met174Val)	2 (0.44)	2 (0.18)	1 (0.06)	-	1 (0.27)	2 (0.03)	4 (0.08)
		p.(Leu238Pro)	-	-	-	-	-	2 (0.03)	-
TOTAL AD			7 (1.56)	10 (0.92)	3 (0.68)	4 (0.94)	1 (0.27)	18 (0.30)	6 (0.13)
FTD	GRN	p.(Arg110*)	1 (0.22)	4 (0.37)	-	-	-	1 (0.02)	-
		p.(Thr382fs)	1 (0.22)	3 (0.28)	1 (0.23)	-	-	-	-
		p.(Arg493*)	-	-	-	-	-	4 (0.04)	-
		p.(Cys521Tyr)	-	-	-	-	-	2 (0.03)	-
	MAPT	p.(Gly289Arg)	-	-	-	-	-	-	1 (0.02)
		p.(Arg406Trp)	-	-	-	1 (0.24)	1 (0.27)	4 (0.07)	-
		p.(Gln424Lys)	1 (0.22)	3 (0.28)	-	-	-	-	-
	TARDBP	p.(Asn267Ser)	-	-	-	-	-	2 (0.03)	-
		p.(Asn390Ser)	-	-	-	-	-	1 (0.02)	-
	VCP	p.(Arg155His)	1 (0.22)	1 (0.09)	-	-	-	-	-
TOTAL FTD			4 (0.88)	11 (1.01)	1 (0.23)	1 (0.24)	1 (0.27)	14 (0.24)	1 (0.02)
PD	LRRK2	p.(Gly2019Ser)	1 (0.22)	3 (0.28)	1 (0.23)	-	-	-	-
	PARK2	p.(Gln34fs)	1 (0.22)	1 (0.09)	-	2 (0.47)	-	3 (0.05)	3 (0.06)
		p.(Pro113fs)	3 (0.67)	4 (0.37)	-	-	-	2 (0.03)	2 (0.04)
		p.(Met192Leu)	2 (0.44)	4 (0.37)	1 (0.23)	1 (0.24)	1 (0.27)	13 (0.22)	11 (0.23)
		p.(Thr240Met)	-	-	-	1 (0.24)	1 (0.27)	3 (0.05)	2 (0.04)
		p.(Leu283Pro)	-	-	-	-	-	-	1 (0.02)
		p.(Arg366Trp)	-	-	-	-	2 (0.53)	-	-
		p.(Gly430Asp)	-	-	-	-	-	-	1 (0.02)
	PINK1	p.(Arg464His)	-	-	-	-	-	1 (0.02)	-
		p.(Arg492*)	1 (0.22)	1 (0.09)	1 (0.23)	-	-	1 (0.02)	3 (0.06)
TOTAL PD			8 (1.77)	13 (1.19)	3 (0.68)	4 (0.94)	4 (1.06)	23 (0.39)	23 (0.48)
TOTAL_ADFTDPD			19 (4.22)	34 (3.12)	7 (1.59)	11 (2.59)	6 (1.59)	55 (0.94)	30 (0.63)

* Reported pathogenic variants in <http://www.molgen.ua.ac.be/ADMutations/> and <http://www.molgen.vib-ua.be/PDMutDB/>

** Genomic and positions correspond to GRCh37 genomic reference build.

<https://doi.org/10.1371/journal.pgen.1007045.t001>

(AAO) in their 50s were carriers of a known pathogenic APP variant, p.(Ile716Val) [53]; and variant APP p.(Val717Phe) [54] was found in one affected individual (AAO = 70) of the ADSP

Table 2. Segregation pattern of reported pathogenic mutations detected in the familial cohort (452 families). The number of carriers and non-carriers in both affected and cognitively normal family members is displayed, along with the average AAO for cases and average ALA for controls. The first reference for each variant is also provided.

Disease	Gene	Protein change	Ref	Family #	N cases (AAO)		N controls (ALA)	
					Carriers	Non-carriers	Carriers	Non-carriers
AD	<i>PSEN1</i>	p.(Ala79Val)	[46]	1	4 (70.75)	4 (73.5)	2 (67.5)	9 (80.7)
AD	<i>PSEN1</i>	p.(Leu85Pro)	[47]	2	1 (75)	3 (81 ± 3)	0	2 (78 ± 0)
AD	<i>PSEN1</i>	p.(Gly206Ala)	[48]	3	1 (55)	0	0	0
AD	<i>PSEN1</i>	p.(Arg269Gly)	[50]	4	1 (40)	0	0	0
AD	<i>PSEN2</i>	p.(Asn141Ile)	[51]	5	1 (45)	0	0	0
AD	<i>PSEN2</i>	p.(Met174Val)	[52]	6	1 (60)	5 (66 ± 8)	1 (79)	0
				7	0	5 (68 ± 9)	1 (76)	3 (78 ± 2)
FTD	<i>GRN</i>	p.(Arg110*)	[61]	8	4 (69 ± 3)	1 (67)	0	0
FTD	<i>GRN</i>	p.(Thr382fs)	[62]	9	3 (64 ± 4)	1 (73)	0	2 (72 ± 4)
FTD	<i>MAPT</i>	p.(Gln424Lys)	PC*	10	3 (70 ± 3)	2 (67 ± 4)	0	1 (83)
FTD	<i>VCP</i>	p.(Arg155His)	[69]	11	1 (56)	0	0	0
PD	<i>LRRK2</i>	p.(Gly2019Ser)	[71]	12	2 (61 ± 0)	2 (68 ± 5)	1 (92)	0
				13	1 (65)	1 (69)	0	2 (86 ± 5)
PD	<i>PARK2</i>	p.(Gln34fs)	[73]	14	1 (79)	1 (82)	0	1 (84)
PD	<i>PARK2</i>	p.(Pro113fs)	[75]	15	2 (80 ± 4)	2 (74 ± 4)	0	1 (81)
				16	1 (86)	2 (65 ± 5)	0	1 (81)
				17	1 (78)	2 (80 ± 3)	0	0
PD	<i>PARK2</i>	p.(Met192Leu)	[76]	18	3 (79 ± 5)	0	1 (80)	0
				19	1 (55)	0	0	0
PD	<i>PINK1</i>	p.(Arg492*)	[80]	20	1 (68)	2 (59 ± 1)	1 (73)	1 (76)

Reported pathogenic variants in <http://www.molgen.ua.ac.be/ADMutations/> and <http://www.molgen.vib-ua.be/PDMutDB/>

Genomic and positions correspond to GRCh37 genomic reference build.

*PC: personal communication in 2005 by Brice to AD&FTDMDB Curator.

<https://doi.org/10.1371/journal.pgen.1007045.t002>

cohort. The *PSEN1* variant p.(Leu226Arg) [55] was detected in one affected participant (AAO = 51) of the KANL cohort; variants *PSEN1* p.(His214Tyr) [56] and p.(Val412Ile) [57] were found in two cases (85 yrs and 84 yrs AAO) and variant p.(Ala409Thr) [58] was found in one cognitively normal participant (ALA = 89) of the ADSP cohort. *PSEN2* variant p.(Ala85-Val) [59] was detected in one cognitively normal participant (ALA = 89) and variant p.(Leu238Pro) [60] was found in two cases (80 and 63 yrs AAO) of the ADSP cohort.

Known FTD pathogenic variants

Mutations in FTD genes are also known to segregate in a dominant pattern. Among the seven FTD genes examined, we observed four pathogenic variants in *GRN*, three pathogenic variants in *MAPT*, two variants in *TARDBP* and one pathogenic variant in *VCP*. We also found the repeat expansion *C9ORF72* in several unrelated cases (0.85%) and in 10 individuals with family history.

The *GRN* variant p.(Arg110*) [61] was present in three siblings and one cousin of a family with a history of reported AD (Fam #8, Fig 1C), but only three of the affected members were carriers of the genetic variant. This variant was also detected in one affected participant (AAO = 74) of the ADSP cohort. The *GRN* variant p.(Thr382fs) [62] was detected in a female AAO 60 yr with an AD diagnosis from the sporadic dataset. After examination of her clinical history it was discovered that she had two siblings and one cousin diagnosed with dementia (Fam #9). Genotyping of this variant in six family members revealed that the genetic variant




Fig 1. Pedigree structure of families' carriers of genetic variants. (a) *PSEN1* p.(Ala79Val), (b) *PSEN2* p.(Met174Val), (c) *GRN* p.(Arg110*). Age at onset (AAO), age at last assessment (ALA) and APOE status is provided for each genotyped individual.

<https://doi.org/10.1371/journal.pgen.1007045.g001>

was present in all members affected by dementia, and one young cognitively normal participant (ALA = 65). Pathology reports available indicated that the index individual had AD pathology and Pick bodies with a frontotemporal lobar atrophy pattern consistent with Pick's disease; and the two siblings were later pathologically diagnosed as FTD and as non-AD dementia. Two other variants in *GRN* p.(Arg493*) [63] and p.(Cys521Tyr) [64] were detected in the sporadic ADSP cohort: *GRN* p.(Arg43*) was found in 4 affected participants (average AAO = 73) and p.(Cys521Tyr) was found in 2 affected participants (average AAO = 82.5). The incomplete penetrance observed for *GRN* within the families can be the result of phenocopies (Fam #8) or presymptomatic cases (Fam #9).

The *MAPT* variant p.(Gly389Arg) [65] was found in one cognitively normal participant (ALA = 91) from the ADSP cohort. *MAPT* variant p.(Arg406Trp) [66] was detected in two participants of the sporadic dataset, both cognitively normal in their 60s with no symptoms of presymptomatic AD (not by imaging or CSF Aβ levels). *MAPT* variant p.(Gln424Lys) (personal communication in 2005 by Brice to AD&FTDMDB Curator) was detected in one family (Fam #10) in which three of the five affected members were carriers of the variant.

Variants in *TARDBP* were exclusively found in the ADSP cohort. Variant p.(Asn267Ser) [67] was detected in two affected members (Average AAO = 77) and variant p.(Asn390Ser) [68] was detected in one affected member with AAO 74 yrs.

The *VCP* variant p.(Arg155His) [69] was detected in Fam #11 but segregation could not be performed since DNA was only available for one of the affected members.

Known PD pathogenic variants

Mutations in PD genes present different patterns of segregation; *SNCA* and *LRKK2* are known to cause dominantly inherited PD, whereas *PARK2*, *PARK7* and *PINK1* are known to cause

early onset PD with a recessive inheritance mode [70]. We detected 10 different known pathogenic PD variants in *LRKK2*, *PARK2* and *PINK1*, in 70 different carriers, all of whom were heterozygous for the variant. One *LRRK2* variant, p.(Gly2019Ser) [71], was only present in two families (Fam #12, Fam #13). Fam #12 includes five members, four diagnosed with AD (two carriers) and one cognitively normal (a carrier heterozygous for p.(Gly2019Ser)). Fam #13 is composed of two affected individuals (one carrier) and two cognitively normal (no carriers). Mutations in the *LRRK2* gene are the most common genetic cause of PD; but this gene is also known to have pleomorphic pathology [72] and the penetrance of the variant p.(Gly2019Ser) is known to vary in different populations and ages [73], so, the incomplete penetrance observed here is not surprising.

Seven variants were detected in *PARK2*: p.(Gln34fs) [74] was found in one case (AAO = 79) from Fam #14 although the other case was a non-carrier, in two affected participants (AAO of 31 and 82 yrs) of the KANL sporadic dataset, and in three cases (average AAO = 83) and three cognitively normal participants (average ALA = 86) from ADSP. *PARK2* variant p.(Pro113fs) [75] was present in four of 10 cases from three families (Fam #15, Fam #16, Fam #17) and in two cases (AAO 73 and 83 yrs) and two cognitively normal (ALA 64 and 87) participants of the ADSP cohort. In our study, variant *PARK2* p.(Met192Leu) [76] was the most common of the PD mutations. All four members from Fam #18 (three cases and one control) were carriers of the genetic variant, as was the case from Fam #19 (AAO = 55). Within the KANL this variant was found in one affected (AAO = 64) and one cognitively normal (ALA = 68) member. Up to 13 affected carriers (Average AAO = 88 ± 7) and 11 cognitively normal carriers (average ALA = 84 ± 5) were detected in the ADSP cohort. Four other variants in *PARK2* were exclusively found in the sporadic cohorts. Variant p.(Thr240Met) [77] was detected in one affected (AAO = 77) and one cognitively normal (ALA = 64) member of the KANL sporadic cohort, and in three affected (average AAO = 82 ± 10) and two cognitively normal (average ALA = 88) members of the ADSP sporadic cohort. *PARK2* variants p.(Leu238Pro) [78] and p.(Gly430Asp) [76] were found in the same cognitively normal individual of the ADSP cohort (ALA = 68), whereas *PARK2* p.(Arg366Trp) [79] was found in two non-affected carriers (average ALA = 65) from the KANL sporadic cohort.

Finally, two variants were detected in *PINK1*. Variant p.(Arg464His) was found in one affected (AAO = 86) participant of the ADSP cohort. Variant p.(Arg492*) [80] was present in only one case (AAO = 68) and one cognitively normal (ALA = 73) member from Fam #20, and in one affected (AAO = 65) and three non-affected (ALA 73,86,88) individuals from the ADSP cohort.

Mutations in *PARK2* and *PINK1* are known to cause early onset PD (AAO range 12–58 yr) with a recessive pattern of inheritance. Segregation could not be determined in our study due to lack of familial stages. With the exception of the case in Fam #20 (AAO of 55), the individuals reported here all had an AAO > 60, suggesting that these *PARK2* and *PINK1* variants would be modifiers rather than causative of AD. For a full description of all known pathogenic variants detected, see Supplementary Results.

Gene based analysis

Once we confirmed that known pathogenic mutations in the AD, FTD and PD genes can be found in sporadic as well as in late-onset familial samples, we wanted to determine if an overall increase of low frequency non-synonymous coding variants can be found in these genes in AD cases compared to cognitively normal participants. We performed this analysis in our unrelated dataset and in the sporadic ADSP dataset. The cases in the unrelated KANL dataset present a larger enrichment of rare pathogenic variants compared to the cases of the sporadic

Table 3. Burden test for KANL and ADSP unrelated datasets. Collapsing and combine (CMC) test of rare variants by Fisher's exact test for (i) variants with a $MAF \leq 1\%$ and categorized to have a high or moderated effect ($MAF \leq 1\%$ HM) and (ii) singleton variants categorized to have a high or moderated effect (AC1 HM), for the unrelated datasets analyzed in this study (unrelated KANL and Sporadic ADSP). Number of polymorphic variants (N), odds ratio (OR) and two sided pvalue (P) are given. Enriched genes with nominally significant pvalues are bold highlighted.

Disease	Gene	$MAF \leq 1\%$ HM						AC1 HM					
		Unrelated KANL (N = 1235)			Sporadic ADSP (N = 10280)			Unrelated KANL (N = 1235)			Sporadic ADSP (N = 10280)		
		N	OR	P	N	OR	P	N	OR	P	N	OR	P
AD	<i>APP</i>	19	1.522	0.340	93	0.958	0.396	15	3.106	0.103	31	1.122	0.688
AD	<i>PSEN1</i>	10	3.380	0.122	51	1.656	0.990	10	3.380	0.122	23	1.520	0.880
AD	<i>PSEN2</i>	24	1.011	1.000	74	0.897	0.123	11	1.471	0.763	18	0.810	0.414
AD	<i>PRNP</i>	3	1.259	0.762	28	1.001	0.534	2	0.838	1.000	8	5.677	0.991
FTD	<i>CHMP2B</i>	7	2.238	0.059	25	0.878	0.243	4	NA	0.130	10	0.202	0.026
FTD	<i>FUS</i>	12	0.552	0.159	61	0.976	0.463	9	0.416	0.315	18	0.648	0.246
FTD	<i>GRN</i>	26	0.656	0.119	94	1.044	0.679	19	1.444	0.494	12	4.056	0.991
FTD	<i>MAPT</i>	33	1.101	0.791	97	0.905	0.178	23	0.639	0.299	37	1.064	0.635
FTD	<i>TARDBP</i>	4	1.118	1.000	19	0.867	0.197	2	NA	0.503	8	0.810	0.517
FTD	<i>TBK1</i>	18	0.956	1.000	77	1.207	0.902	13	2.820	0.160	22	1.419	0.843
FTD	<i>VCP</i>	15	0.727	0.459	41	1.071	0.701	12	0.595	0.398	9	6.489	0.995
PD	<i>LRRK2</i>	54	1.142	0.591	267	0.994	0.488	38	0.705	0.318	43	1.461	0.910
PD	<i>PARK2</i>	20	0.831	0.577	82	0.971	0.407	9	1.048	1.000	31	1.284	0.804
PD	<i>PARK7</i>	8	1.471	0.763	30	0.916	0.389	6	1.680	0.694	18	1.274	0.768
PD	<i>PINK1</i>	29	0.935	0.866	91	0.893	0.212	23	0.835	0.673	27	1.105	0.671
PD	<i>SNCA</i>	3	1.399	0.734	11	0.866	0.283	2	NA	0.503	-	-	-
PD	<i>UCHL1</i>	6	1.682	0.521	31	1.045	0.621	5	3.365	0.384	11	2.162	0.933
PD	<i>ATP13A2</i>	51	0.750	0.149	195	0.837	0.006	32	1.018	1.000	79	0.897	0.357
PD	<i>GIGYF2</i>	30	0.769	0.402	165	1.040	0.692	22	0.623	0.377	70	1.146	0.752
PD	<i>HTRA2</i>	11	1.231	0.595	50	1.196	0.909	6	0.166	0.098	25	0.636	0.176
PD	<i>PLA2G6</i>	40	0.976	1.000	136	0.999	0.510	26	0.977	1.000	17	0.911	0.518
PD	<i>FBXO7</i>	20	1.452	0.322	71	1.030	0.611	17	1.200	0.809	42	1.035	0.603
PD	<i>VPS35</i>	7	6.771	0.045	46	0.913	0.361	5	3.365	0.384	30	0.868	0.421
PD	<i>EIF4G1</i>	40	1.713	0.010	204	1.016	0.606	26	1.146	0.843	100	0.954	0.447
PD	<i>DNAJC16</i>	29	1.404	0.186	143	0.918	0.227	20	1.567	0.374	69	0.833	0.262
ALS	<i>SOD1</i>	1	0.000	0.208	8	0.810	0.327	-	-	-	1	NA	1.000
ALS	<i>OPTN</i>	14	0.835	0.684	68	1.092	0.750	12	0.836	0.779	30	1.060	0.631
ALS	<i>UBQLN2</i>	5	1.688	0.346	-	-	-	-	-	-	-	-	-
ALS	<i>PFN1</i>	1	0.000	0.456	18	1.128	0.716	1	0.000	0.456	3	1.621	0.831
ALS	<i>SQSTM1</i>	30	0.758	0.271	99	0.945	0.295	22	0.694	0.399	24	0.957	0.537
	TOTAL AD	56	1.174	0.439	246	0.988	0.443	38	2.315	0.028	80	1.283	0.885
	TOTAL FTD	115	0.877	0.378	414	0.980	0.367	82	1.057	0.907	116	1.092	0.711
	TOTAL PD	348	1.049	0.688	1522	0.976	0.276	237	0.897	0.492	562	1.013	0.573
	TOTAL ALS	51	0.823	0.367	193	0.980	0.410	35	0.698	0.307	58	1.070	0.649

<https://doi.org/10.1371/journal.pgen.1007045.t003>

ADSP dataset (Table 3). In both datasets, the enrichment increases when we focus on very rare non-synonymous variants (Table 3). None of these enrichments was significant after multiple test correction, but we observe some suggestive and nominally significant results.

Within the unrelated KANL cohort we found *CHMP2B* (OR = 2.24, $P = 0.06$) and *VPS35* (OR = 6.77, $P = 0.05$) to have suggestive significance-values, and *EIF4G1* (OR = 1.71, $P = 0.01$) to be nominally significant for rare variants, those with minor allele frequency below 1% and a predicted high or moderate effect on the final protein ($MAF \leq 1\%$ HM). Also, the global effect of AD genes (*APP*, *PSEN1* and *PSEN2*) was nominally significant (OR = 2.31, $P = 0.028$) if we

considered only very rare variants, those with just one allele count in the population and a predicted high or moderate effect on the final protein (AC1 HM).

The enriched effect of *CHMP2B* remained significant when we considered only APOE $\epsilon 4$ carriers; some of the AD genes became nominally significant (e.g. *APP* and *PSEN2*) and the global effect of AD genes resulted in nominal significance for rare variants and significant after multiple test correction (Total AD, OR = 14.76, $P = 1.83 \times 10^{-4}$) when we considered very rare variants (S3 Table). *EIF4G1* remained nominally significant (OR = 2.01, $P = 0.02$) for the set of APOE $\epsilon 4$ non-carriers; *FBXO7* became nominally significant (OR = 3.09, $P = 0.03$) and *VPS35* gained suggestive significance (OR = 7.05, $P = 0.06$) within the set of rare variants ($MAF \leq 1\%$ HM). In addition, the global effect of very rare variants (AC1 HM) from FTD genes was also nominally significantly associated (OR = 1.84, $P = 0.04$) with APOE $\epsilon 4$ non-carriers (S4 Table).

Within the sporadic ADSP cohort, none of the enriched genes presented significant p-values (Table 3). However, *PSEN1* resulted in nominally significant association with the APOE $\epsilon 4$ non-carrier for both sets, rare (OR = 2.14, $P = 0.05$) and very rare variants (OR = 2.76, $P = 0.02$) (S3 Table).

Because the lack of significant associations could be due to the sample size, we decided to perform gene-based analyses comparing all the unrelated KANL cases ($n = 672$) or the sporadic ADSP cases ($N = 5,679$) with the non-Finnish European (NFE) ExAC population as a cognitive normal dataset ($n = 33,000$). The coverage of the tested genes in ExAC and in our population is comparable. *PSEN1* appeared as nominally significantly enriched in these two cohort cases for the set of rare variants ($MAF \leq 1\%$ HM); and it was statistically significant for sporadic ADSP cases within the very rare set of variants (OR = 3.134, $P = 3.34 \times 10^{-5}$). Interestingly, *PINK1* appeared as significantly associated with the unrelated cases examined regardless of the set of variants tested. *EIF4G1* also remained significantly associated with unrelated KANL cases within the rare variants subset (OR = 1.69, $P = 8.96 \times 10^{-4}$) and for sporadic ADSP cases within the very rare set of variants (S5 Table). No statistical association was found for the overall AD, FTD and PD genes in either the KANL or ADSP dataset (S5 Table).

Discussion

Recent reports indicate that rare variants in AD Mendelian genes, *APP*, *PSEN1* and *PSEN2*, cause, contribute and modify risk for AD [12,45]. Given the clinical and pathologic overlap between AD and other common neurodegenerative diseases, a genetic contribution toward AD risk by genes involved in other diseases has been sought for some time now. However, because of their rarity, contributions towards disease at a genome-wide level of significance are difficult to achieve without large cohorts and well characterized populations. This is the first study that thoroughly screens for pathogenic mutations in known neurodegenerative genes and evaluates the contribution of low frequency variants in these genes towards AD in a large cohort of sporadic and densely affected LOAD families.

In previous studies, we sequenced *APP*, *PSEN1*, *PSEN2*, *GRN*, *MAPT* and *C9ORF72* in late-onset families and detected known pathogenic mutations in 2.9% of the families [45,81]. In this study, we detected 10 families (2.2%) with carriers of a known pathogenic mutation in *APP*, *PSEN1*, *PSEN2*, *GRN* or *MAPT*, and an additional 0.57% of the families with the *C9ORF72* repeat. Overall, 0.82% fLOAD participants carried a mutation in AD genes, and 0.63% of them carried a mutation in FTD genes.

This study extends previous findings to sporadic cases, from two different cohorts: sporadic cases from the Knight-ADRC (KANL) and late-onset cases and cognitively normal participants from the ADSP. We found that 0.87% of the KANL participants carry a known pathogenic

mutation in AD (0.94% of cases and 0.27% of controls) and FTD (0.24% of cases and 0.27% of controls) genes, and 0.36% of the ADSP participants carry a known pathogenic mutation in AD (0.30% of cases and 0.13% of controls) and FTD (0.24% of cases and 0.02% of controls) genes. This suggests that it is possible to find known pathogenic mutations of AD and FTD genes in familial LOAD as well as sporadic AD with the same probability. Another important finding is that we found a similar portion of cases and families with a mutation in the AD genes vs the FTD genes. Mutations in AD genes were found in 0.82% of fLOAD participants and FTD genes in 0.63% of that population. It is important to note that we found that 0.85% of the sporadic KANL cases had the *C9ORF72* expansion repeat that had to be genotyped independently, because current sequencing methods are not able to capture this variant. Nonetheless, the proportion of individuals with FTD genes in the ADSP dataset is underestimated because we could not screen for the *C9ORF72* repeat. It is also important to note that known pathogenic mutations were found in the cognitive normal participants. For this analysis, we only focused on known and well characterized pathogenic mutations. Those variants were classified as pathogenic because they were initially found in early-onset cases, segregated with disease status, were not present in the general population and/or functional analyses confirmed that those variants are pathogenic.

The clinical complexity of dementias has raised speculation that many other neurological diseases are misdiagnosed as AD [82]. In several previous studies there has been the suspicion for FTD to masquerade clinically as AD [57,83]; therefore it could be argued that the detection of known FTD pathogenic variants (*GRN*—p.(Arg110*) and *GRN*- p.(Thr382fs)), or *C9ORF72* in the KANL cohort is due to the presence of misclassified FTD cases. Autopsy reports from some members of these families describe pathological variability among the affected carriers, with some members presenting with AD and Pick body pathology, and others presenting with “frontotemporal nonspecific neuropathology”. Hence, instead of misclassified cases, we may be facing a pleomorphic pathology of these *GRN* variants, an issue observed previously, specifically in familial FTD [84]. This pleomorphism is expanded by the recent association of *GRN* rare variants in autopsy confirmed cases with Lewy Body dementia (LBD) [85].

Pleomorphic pathology has also been described in several instances for *LRRK2* genetic variants [42,71] which, other than being the most common cause for autosomal late onset PD, has also been associated with tau pathology and AD [86,87]. The finding here of a *LRRK2* genetic variant p.(Gly2019Ser) (Fam #13) in a clinically diagnosed AD case would amplify the pleomorphic range of *LRRK2* variants. Alternatively, it could be that the pathogenic PD variants observed in *LRRK2*, *PARK2* and *PINK1* could be misdiagnosed cases of LBD. LBD may initially present with cognitive impairment and be misdiagnosed as AD, or as PD if it starts with parkinsonism. In addition, Lewy bodies, sometimes present in AD, are hallmarks of DLB and PD, and A β plaques and Tau tangles often coexist in LBD and PD, for which a synergy and a genetic correlation among these three conditions has been suggested [88–90].

We have observed that variants usually regarded as causing pure early onset forms of AD, FTD, PD or ALS can be associated with a wide pathological spectrum. They may also present to different extent in families with a late onset. Both highly penetrant variants (*GRN*—p.(Arg110*)), and others with mild penetrance (*PSEN2*—p.(Met174Val)) have been observed. Incomplete penetrance can be (in some instances) explained by the presence of pre-symptomatic cases; but the presence of phenocopies also suggests that the penetrance may not be as high as previously thought. (Fig 1B, Fam #6). There are reported cases in which autosomal dominant AD variants present with a later AAO and clinically mimic LOAD [91]. The observed genetic overlap of AD with other neurodegenerative diseases suggests that future studies focused on gene discovery for AD using late onset families should not rely solely on segregation patterns; additional methods that take into account endophenotypes, gene-networks and pathway analysis need to be developed and implemented in routine analysis.

The confirmation that pathogenic variants in causal Mendelian genes are found in late onset individuals, with or without family history, serves to model the system and alert us as to what we might expect of other genes that potentially carry pathogenic mutations. We observed an enrichment, although not statistically significant, in most of AD, FTD and PD genes in both KANL and ADSP cohorts. The pathological cross-over with ALS genes would not be so obvious despite the significant association reported between ADSP cases when compared to ExAC population. Nevertheless, from the results of this study we can observe that there are certainly molecular crossovers between AD, FTD, PD and ALS that point towards common etiologic pathways. These gene-based analyses performed suggest an enrichment of non-synonymous rare variants in these Mendelian genes in the cases of both cohorts, KANL and ADSP; this enrichment is stronger when we only consider very rare variants (AC1 HM), although none of the analysis was statistically significant. Only *PSEN1* and *PINK1* showed a consistent and steady association pattern when we compared the cases from KANL or ADSP against ExAC as cognitive normals. Therefore, the lack of genome-wide significant p-value could be due to power, but other alternative explanations exist. One possibility is that given the late onset appearance of the disease we may be including many potential asymptomatic cases among the cognitively normal cohorts, as we see in some of the families evaluated (Fam #1) and by the identification of sporadic cognitive normals below 70 yrs who are carriers of pathogenic mutations (e.g. *APP* variants p.(Ile716Val) and p.(Val717Phe)). This leads to a reevaluation of current study designs; first, more pathologically confirmed elderly cognitive normals should be incorporated and prioritized. Second, more extensive preliminary screenings should be in place for proper genetic counselling and screening of families before incorporating individuals into studies looking for novel genetic causes. Another possibility is that current analytical and statistical methods are inadequate to detect real causal genes involved in the disease. In this study, we have shown that despite having in our cohort individuals carrying known and causal pathogenic variants, current gene-based analysis would have not detected these genes as implicated in the disease. On the other hand current gene-based methods have been able to find genome-wide p-values for genes enriched for risk, but not pathogenic variants such as *APOE*, *TREM2*, *PLD3*, *ABCA7* and *SORL1* [92–95].

Study limitations

We would like to conclude by reinforcing that despite the limitations of this study the results obtained are sound and in the expected direction. First, this research is based on clinical AD participants and cognitive normals, so we cannot rule out the presence of presymptomatic cases, comorbidities, phenotypic changes with disease evolution, or even misdiagnoses, as we have already stated. This limits the power of this study to establish causality of the detected pathogenic variants and it could as well be limiting our statistical power and enrichment. Second, sporadic and familial AD are categorically different entities, despite the fact that we believe the genetic architecture and molecular load are largely similar [91]. However, the complex and heterogeneous presentation of AD makes it difficult to recruit large cohorts with good phenotypic characterization. Therefore, despite our effort to increase our sample size by creating an unrelated cohort, we are still underpowered to detect significant association for genes that we know are directly involved in the pathogenicity of the disease. Nonetheless, these findings highlight the need to join efforts to gather large sample sizes. Finally, we are also aware that the comparison against ExAC data has some methodological flaws. We even acknowledge the possible presence of pre-symptomatic cases within the Exac database. That is why we only consider those results as illustrative of what could be the genetic load when a larger dataset of cognitive normal participants is available.

Material and methods

Washington University cohort

Samples from the Washington University School of Medicine (WUSM) site included in this study were recruited by either the Charles F. and Joanne Knight Alzheimer's Disease Research Center (Knight-ADRC) at the Washington University School of Medicine in Saint Louis or the National Institute on Aging Genetics Initiative for Late-Onset Alzheimer's Disease (NIA-LOAD). From this point onwards, we will refer to these samples as KANL (Knight-ADRC--NIA-LOAD). This study was approved by each recruiting center's Institutional Review Board. Research was carried out in accordance with the approved protocol. Written informed consent was obtained from participants and their family members by the Clinical and Genetics Core of the Knight ADRC. The approval number for the Knight ADRC Genetics Core family studies is 201104178.

All the cases received a diagnosis of dementia of the Alzheimer's type (DAT), using criteria equivalent to the National Institute of Neurological and Communication Disorders and Stroke-Alzheimer's Disease and Related Disorders Association for probable AD [96,97]. Cognitively normal participants received the same assessment as the cases, and were deemed non-demented. Written consent was obtained from all participants.

Sporadic cohort. The Knight Alzheimer's Disease Research Center (Knight ADRC) at the WUSM recruits volunteer participants for longitudinal studies of aging and dementia [98]. We selected 424 cases clinically diagnosed with possible or probable AD [96] and 377 cognitively normal participants with a Clinical Dementia Rating (CDR) of 0 (no dementia) at last assessment.

Familial cohort. The NIA-LOAD Family Study has recruited multiplex families with two or more siblings affected with LOAD across the United States. A description of these samples has been reported previously [99]. We selected individuals for sequencing from families (described previously [45]) in which APOE ϵ 4 did not segregate with disease status, and in which the proband of the family did not carry any known mutation in *APP*, *PSEN1*, *PSEN2*, *MAPT*, *GRN* or *C9ORF72*. The final cohort consisted in 1,402 samples from 430 families, of which 997 were clinically diagnosed as AD, 418 were relatives with CDR = 0 at last assessment, and 51 were cases initially diagnosed as AD but turned out to have another diagnosis (OT) after pathological examination.

Unrelated cohort. To perform burden tests, we generated a cohort of unrelated European American individuals by combining the sporadic cohort (CA and CO) with the youngest case of each family and an unrelated CO (usually a marry-in). To ensure unrelatedness we calculated Identity by Descent (IBD) with PLINK1.9 and required that in addition to an $IBD \leq 0.2$, all possible pairs had a $Z_0 \geq 0.75$ and a $Z_1 \leq 0.25$. To ensure all individuals were from European American ethnicity we ran PCAs against the 1000G database. This resulted in an unrelated case-control dataset of 1,235 individuals (672 cases and 563 controls) (Table 4).

ADSP cohort

The Alzheimer's Disease Sequencing Project (ADSP) is a collaborative work of five independent groups across the USA that aims to identify new genomic variants contributing to increased risk for LOAD. (<https://www.niagads.org/adsp/content/home>). During the discovery phase, they generated WGS data from members of multiplex AD families and whole exome sequence WES data collected in a large case-control cohort. These data are available to qualified researchers through the database of Genotypes and Phenotypes (<https://www.ncbi.nlm.nih.gov/gap> Study Accession: phs000572.v7.p4).

Table 4. Demographic data for the cohorts employed in this study and analysis plan.

		N	Age±SD	Age*(range)	Sex (Fe)	APOE4+	Analysis
Familial KANL & ADSP		1582					
	Cases	1090	72.30±9.20	36–99	63%	72%	Discovery
	Controls	441	83.95±8.95	39–104	58%	52%	
	Other	51	88.18±8.70	66–108	61%	50%	
Sporadic KANL		801					
	Cases	424	66.13±9.77	43–89	49%	60%	Discovery
	Controls	377	71.93±10.11	41–106	57%	37%	
Unrelated KANL		1235					
	Cases	672	65.59±9.29	36–98	52%	70%	GENE-based
	Controls	563	77.46±8.63	41–106	55%	40%	
Sporadic ADSP		10909					Discovery
	Cases	5844	75.50±9.33	40–107	58%	42%	
	Controls	4767	86.78±5.47	42–107	59%	15%	
	Other	298	86.19±6.73	64–104	57%	25%	
Sporadic ADSP (EU only)		10280					GENE-based
	Cases	5679	75.51 ± 8.83	40–107	58%	42%	
	Controls	4601	84.72 ± 4.72	49–107	52%	15%	

* Age At Onset (AAO) for cases and Age at Last Assessment (ALA) for controls.

<https://doi.org/10.1371/journal.pgen.1007045.t004>

Sporadic cohort. The case-control cohort on ADSP consists of 10,909 individuals, 5,844 cases, 4,767 cognitive normal participants and 298 reported as OT, mostly of European-American ancestry (98%). We downloaded a plink file available for sequence data after joint calling and QC analysis. We used the entire dataset to search for presence of pathogenic variants but we later restricted our working dataset to 10,280 IDs (5,679 cases and 4,601 controls) of European-American ethnicity corroborated by PCAs.

Familial cohort. The familial cohort of the ADSP consists of 582 individuals from 111 multiplex AD families from European-American, Caribbean Hispanic, and Dutch ancestry (Details about the samples are available at NIAGADS). We downloaded raw data (.sra format) from dbGAP for 143 IDs (113 cases and 23 controls) from 37 multiplex families of European-American ancestry that were incorporated with the KANL familial dataset.

Sequencing

Samples coming from the KANL site were sequenced using either whole-exome sequencing (WES, 83.53%) or whole-genome sequencing (WGS, 16.46%). Exome libraries were prepared using Agilent’s SureSelect Human All Exon kits V3 and V5 or Roche VCRome. Both, WES and WGS samples were sequenced on a HiSeq2000 with paired ends reads, with a mean depth of coverage of 50x to 150x for WES and 30x for WGS.

Bioinformatic analysis and QC

We performed joint analysis and quality control (QC) for all samples coming from the KANL site as well as for the ADSP familial study-design downloaded from dbGAP. Whether we started from BAM files or SRA files, all were converted to fastq files. Alignment was conducted against GRCh37.p13 genome reference. Variant calling was performed separately for WES and WGS following GATK’s 3.6 Best Practices (<https://www.broadinstitute.org/gatk/>) and restricted to Agilent’s V5 kit plus a 100 bp of padding added to each capture target end. WGS

data was filtered to remove low complexity regions, and regions with excessive depth. Only those variants and indels that fell within the above 99.9% confidence threshold were considered for analysis; additional variant filters included allele-balance ($AB = 0.3-0.7$), quality depth ($QD \geq 5$ for indels and $QD \geq 2$ for SNPs), and missingness ($geno = 0.05$). Variants out of Hardy Weinberg equilibrium ($P < 1 \times 10^{-6}$) or with differential missingness between cases and controls, WES and WGS or different sequencing platforms were removed from analysis. In addition, individuals with more than 10% of missing variants and whose genotype data indicated a sex discordant from the clinical database were removed from dataset. Finally, individual and familial relatedness was confirmed using PLINK1.9 (<https://www.cog-genomics.org/plink2/ibd>) and an existing GWAS dataset for these individuals. Functional impact and population frequencies of variants were annotated with SnpEff [100]. At this point we separated familial from sporadic KANL datasets and generated the unrelated dataset.

For the ADSP case-control dataset we downloaded plink file after alignment, variant calling and QC had been performed to which we performed additional QC. Briefly, we checked for allele-balance ($AB = 0.3-0.7$) and differential missingness between cases and controls. We used the entire dataset for discovery of pathogenic variants but we later restricted our analysis to individuals with self-reported non-hispanic white ethnicity that we corroborated with PCAs.

C9ORF72 hexanucleotide repeat genotyping. The presence of the expanded hexanucleotide repeat and the number repeats for the longest allele was determined by previously reported methods for both a modified repeat-primed PCR and a fluorescence-based fragment size analysis as previously reported [80,101,102]. Briefly, repeat-primed PCR was performed containing 100 ng genomic DNA, 1x FastStart PCR Master Mix (Roche Applied Science, Indianapolis, IN, USA), 3.5% DMSO, 1x Q solution (Quiagen, Valencia, CA) and 0.18 mM of deazaGTP (NEB, Ipswich, MA). PCR products were run on a Genetic Analyzer 3500 (Applied Biosystems) and analyzed using GeneMapper. A sample was considered positive for a repeat expansion when assay replicates demonstrated >30 peaks and a decrementing saw-tooth pattern with 6 bp periodicity.

Selection of candidate genes, variants and analysis

We focused our analysis on genes and variants reported as pathogenic and causing disease in a Mendelian pattern in AD, FTD, PD or ALS. For AD and FTD we restricted our analysis to those genes listed in the AD&FTD mutation database (<http://www.molgen.vib-ua.be/ADMutations/>, accessed November, 2016); particularly, we focused on *APP*, *PSEN1* and *PSEN2* for AD and *CHMP2B*, *FUS*, *GRN*, *MAPT*, *TARDBP*, *TBK1* and *VCP* for FTD. For PD we started off with those genes and variants listed in the PD mutation database (<http://www.molgen.vib-ua.be/PDMutDB/>, accessed November, 2016), namely, *LRRK2*, *PARK2*, *PARK7*, *PINK1* and *SNCA*; we also included *UCHL1*, *ATP13A2*, *GIGYF2*, *HTRA2*, *PLA2G6*, *FBXO7*, *VPS35*, *EIF4G1* and *DNAJC16* for being reported as causative of Mendelian PD in several occasions [103,104]. To our knowledge, there is no ALS mutation database so we restricted our analysis to those genes consistently reported in the literature as causative of familial ALS, i.e. *SOD1*, *OPTN*, *UBQLN2* and *PFN1* [37]; other familial ALS genes like *FUS*, *VCP*, *UBQLN2* and *SQSTM1* are included as FTD causing.

Single variant analysis: Known pathogenic variants. The AD & FTD and PD mutation databases are continuously updated with information on genetic variants, reported in the literature, at scientific meetings or via direct submission (pathogenic or not) that occur in the coding region of genes related to AD, FTD, and PD. We screened our sporadic and familial cohorts for presence of already reported pathogenic variants and evaluated their pattern of segregation in the familial dataset.

Gene-based analysis. We sought to estimate whether our cohort was enriched in low frequency variants in the AD, FTD, PD, ALS genes. To estimate the effect size of low frequency variants in a gene-based context we performed exact CMC (Collapsing and combine rare variants) burden test, as implemented in *rvtest* [105] for each gene and aggregated set of genes that confer risk towards AD, FTD, PD and ALS. Burden analysis was performed within the cases of the KANL unrelated cohort (671 cases, 563 controls) and within the cases of the ADSP dataset and the ExAC non-Finnish European cohort as controls. Only those variants predicted to have a high (frameshift, splice acceptor/donor, stop gained/lost), or moderate (in-frame deletion/insertion, missense variant) effect according to SnpEff [100] were included. We further applied two frequency filters (i) a minor allele frequency below 1% (using ExAC non-Finnish European frequency as cut-off) and considered having a high or moderate (HM) effect ($MAF \leq 1\%$ HM), (ii) those variants with allele count equal to one (using the ExAC non-Finnish European counts as cut-off) and considered to have a high or moderate (HM) effect. The second threshold AC1 is based on the frequency of variant *PSEN1* rs63749824, p.(Ala79Val) (a known AD pathogenic variant) in the ExAC non-Finnish European dataset. Any variant more frequent than this conservative threshold would not be expected to be a highly penetrant pathogenic mutation. This methodology has been previously used to reassess the effect of rare variants in Mendelian genes of cardiomyopathy in the general population [106,107]. To evaluate a possible association between the Mendelian genes studied and the APOE status, we performed the previous analysis stratified by APOE status.

We performed a second burden analysis among our unrelated cases (672 cases) or the ADSP cases (5679) and the non-Finnish European (NFE) ExAC reference population (33,000 controls) [108]. Similarly, for the gene-based analysis in the unrelated dataset, we performed a burden test for high or moderate variants with (i) a $MAF \leq 1\%$ and (ii) variants with AC1. Because we do not have individual genotype data for the ExAC dataset we could not use *rvtest* to perform the burden analysis. We instead performed the CMC Fisher corrected using the R package [109] and included in the analysis those variants predicted to have a high (frameshift, splice acceptor/donor, stop gained/lost), or moderate (in-frame deletion/insertion, missense variant) effect according to SnpEff [100]. The frequency of variant *PSEN1* rs63749824, p.(Ala79Val) in the NFE ExAC dataset is also one allele count in 33,000 sequenced individuals. Despite the fact that ExAC cannot be regarded as a pure control dataset, there are several studies that have used this resource as a proxy for studying variation in the human population, with the hypothesis that variants absent in ExAC are more likely to be pathogenic [106,107].

Supporting information

S1 Table. Relation of previously reported pathogenic variants detected.

(DOCX)

S2 Table. Differential frequency test (Fisher and Chi-Squared) for pathogenic variants.

(DOCX)

S3 Table. Burden test for APOE $\epsilon 4$ carriers from KALN and ADSP unrelated datasets.

(DOCX)

S4 Table. Burden test for APOE $\epsilon 4$ non-carriers from unrelated KANL and sporadic ADSP datasets.

(DOCX)

S5 Table. Burden test for WASHU and ADSP unrelated cases vs ExAC non-Finnish European (NFE) as controls.

(DOCX)

S1 Results. Full description of all known pathogenic variants detected. (DOCX)

Acknowledgments

We thank the contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine. Members of the National Institute on Aging Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD NCRAD) Family Study Group include the following: Richard Mayeux, MD, MSc; Martin Farlow, MD; Tatiana Foroud, PhD; Kelley Faber, MS; Bradley F. Boeve, MD; Neill R. Graff-Radford, MD; David A. Bennett, MD; Robert A. Sweet, MD; Roger Rosenberg, MD; Thomas D. Bird, MD; Carlos Cruchaga, PhD; and Jeremy M. Silverman, PhD.

Author Contributions

Conceptualization: Carlos Cruchaga.

Data curation: John P. Budde, Ben Saef, Joanne Norton, Rachel Chasse.

Formal analysis: Maria Victoria Fernández, Jong Hun Kim.

Funding acquisition: John C. Morris, Alison Goate, Carlos Cruchaga.

Investigation: Maria Victoria Fernández.

Methodology: Maria Victoria Fernández, Kathleen Black, Alexandra Medvedeva, Yuetiva Deming, Jorge Del-Aguila, Laura Ibañez, Umber Dube, Oscar Harari.

Software: John P. Budde.

Supervision: Carlos Cruchaga.

Writing – original draft: Maria Victoria Fernández.

Writing – review & editing: Maria Victoria Fernández, Carlos Cruchaga.

References

1. Lill CM, Bertram L. Towards Unveiling the Genetics of Neurodegenerative Diseases. *Semin Neurol.* 2011; 31(5):531–41. <https://doi.org/10.1055/s-0031-1299791> PMID: 22266890
2. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. *J Clin Invest.* 2005; 115(6):1449–57. <https://doi.org/10.1172/JCI24761> PMID: 15931380
3. Lill CM, Bertram L. Towards unveiling the genetics of neurodegenerative diseases. *Semin Neurol.* 2011; 31(5):531–41. <https://doi.org/10.1055/s-0031-1299791> PMID: 22266890
4. Alzheimer's Association Statistics. (2017). 2017 Alzheimer's Disease Facts and Figures
5. Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biol Psychiatry.* 2015 Jan 1; 77(1):43–51. <https://doi.org/10.1016/j.biopsych.2014.05.006> PMID: 24951455
6. Devi G, Fotiou A, Jyrinji D, Tycko B, DeArmand S, Rogaeva E, et al. Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease. *Arch Neurol.* 2000; 57(10):1454–7. PMID: 11030797
7. Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu C-E, et al. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. *Brain.* 2010; 133:1143–54. <https://doi.org/10.1093/brain/awq033> PMID: 20375137
8. Kamino K, Orr HT, Payami H, Wijsman EM, Alonso ME, Pulst SM, et al. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. *Am J Hum Genet.* 1992 Nov; 51(5):998–1014. PMID: 1415269

9. Rademakers R, Cruts M, van Broeckhoven C. The role of tau (MAPT) in frontotemporal dementia and related tauopathies. *Hum Mutat.* 2004; 24(4):277–95. <https://doi.org/10.1002/humu.20086> PMID: 15365985
10. Mukherjee O, Kauwe JS, Mayo K, Morris JC, Goate AM. Haplotype-based association analysis of the MAPT locus in Late Onset Alzheimer's disease. *BMC Genet.* 2007; 8(3). <https://doi.org/10.1186/1471-2156-8-3> PMID: 17266761
11. Allen M, Kachadoorian M, Quicksall Z, Zou F, Chai H, Younkin C, et al. Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels. *Alzheimers Res Ther.* 2014; 6(4):39. <https://doi.org/10.1186/alzrt268> PMID: 25324900
12. Gerrish A, Russo G, Richards A, Moskvina V, Ivanov D, Harold D, et al. The role of variation at A β PP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. *J Alzheimers Dis.* 2012; 28(2):377–87. <https://doi.org/10.3233/JAD-2011-110824> PMID: 22027014
13. Myers AJ, Kaleem M, Marlowe L, Pittman AM, Lees AJ, Fung HC, et al. The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. *Hum Mol Genet.* 2005; 14(16):2399–404. <https://doi.org/10.1093/hmg/ddi241> PMID: 16000317
14. Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert J-C, Chung J, Naj AC, et al. A novel Alzheimer disease locus located near the gene encoding tau protein. *Mol Psychiatry.* 2016; 21(1):108–17. <https://doi.org/10.1038/mp.2015.23> PMID: 25778476
15. Barber IS, Braae A, Clement N, Patel T, Guetta-Baranes T, Brookes K, et al. Mutation analysis of sporadic early-onset Alzheimer's disease using the NeuroX array. *Neurobiol Aging.* 2017; 49:215.e1–215.e8.
16. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature.* 2006; 442(7105):916–9. <https://doi.org/10.1038/nature05016> PMID: 16862116
17. Fenoglio C, Galimberti D, Cortini F, Kauwe JSK, Cruchaga C, Venturelli E, et al. Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. *J Alzheimers Dis.* 2009; 18(3):603–12. <https://doi.org/10.3233/JAD-2009-1170> PMID: 19625741
18. Lee M-J, Chen T-F, Cheng T-W, Chiu M-J. Variant of Progranulin Gene Is a Risk of Alzheimer's Disease in the Taiwanese Population. *Neurodegener Dis.* 2011; 8(4):216–20. <https://doi.org/10.1159/000322538> PMID: 21212639
19. Brouwers N, Sleegers K, Engelborghs S, Maurer-Stroh S, Gijselink I, van der Zee J, et al. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. *Neurology.* 2008; 71(9):656–64. <https://doi.org/10.1212/01.wnl.0000319688.89790.7a> PMID: 18565828
20. Perry DC, Lehmann M, Yokoyama JS, Karydas A, Lee JJ, Coppola G, et al. Progranulin mutations as risk factors for Alzheimer disease. *JAMA Neurol.* 2013; 70(6):774–8. <https://doi.org/10.1001/2013.jamaneurol.393> PMID: 23609919
21. Seelaar H, Rohrer JD, Pijnenburg Y a L, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. *J Neurol Neurosurg Psychiatry.* 2011; 82(5):476–86. <https://doi.org/10.1136/jnnp.2010.212225> PMID: 20971753
22. Olszewska DA, Lonergan R, Fallon EM, Lynch T. Genetics of Frontotemporal Dementia. *Curr Neurol Neurosci Rep.* 2016; 16(12):107. <https://doi.org/10.1007/s11910-016-0707-9> PMID: 27878525
23. van der Zee J, Gijselink I, Dillen L, Van Langenhove T, Theuns J, Engelborghs S, et al. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. *Hum Mutat.* 2013; 34(2):363–73. <https://doi.org/10.1002/humu.22244> PMID: 23111906
24. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron.* 2011; 72(2):245–56. <https://doi.org/10.1016/j.neuron.2011.09.011> PMID: 21944778
25. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron.* 2011; 72(2):257–68. <https://doi.org/10.1016/j.neuron.2011.09.010> PMID: 21944779
26. Shu L, Sun Q, Zhang Y, Xu Q, Guo J, Yan X, et al. The Association between C9orf72 Repeats and Risk of Alzheimer's Disease and Amyotrophic Lateral Sclerosis: A Meta-Analysis. *Parkinsons Dis.* 2016; 2016:1–8.
27. Majounie E, Abramzon Y, Renton AE, Perry R, Bassett SS, Pletnikova O, et al. Repeat Expansion in C9ORF72 in Alzheimer's Disease. *N Engl J Med.* 2012; 366(3):283–4. <https://doi.org/10.1056/NEJMc1113592> PMID: 22216764
28. Harms M, Benitez BA, Cairns N, Cooper B, Cooper P, Mayo K, et al. C9orf72 Hexanucleotide Repeat Expansions in Clinical Alzheimer Disease. *JAMA Neurol.* 2013; 70(6):736. <https://doi.org/10.1001/2013.jamaneurol.537> PMID: 23588422

29. Kohli MA, John-Williams K, Rajbhandary R, Naj A, Whitehead P, Hamilton K, et al. Repeat expansions in the C9ORF72 gene contribute to Alzheimer's disease in Caucasians. *Neurobiol Aging*. 2013; 34(5):1519.e5–12.
30. Ferrari R, Kapogiannis D, Huey ED, Momeni P. FTD and ALS: a tale of two diseases. *Curr Alzheimer Res*. 2011; 8(3):273–94. PMID: [21222600](#)
31. Bennion Callister J, Pickering-Brown SM. Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS. *Exp Neurol*. 2014; 262:84–90. <https://doi.org/10.1016/j.expneurol.2014.06.001> PMID: [24915640](#)
32. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. *Science* (80-). 2006; 314(5796):130–3. <https://doi.org/10.1126/science.1134108> PMID: [17023659](#)
33. Kwiatkowski TJ, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. *Science*. 2009; 323(5918):1205–8 <https://doi.org/10.1126/science.1166066> PMID: [19251627](#)
34. Koppers M, van Blitterswijk MM, Vlam L, Rowicka PA, van Vught PWJ, Groen EJJ, et al. VCP mutations in familial and sporadic amyotrophic lateral sclerosis. *Neurobiol Aging*. 2012; 33(4):837.e7–13
35. Deng H, Gao K, Jankovic J. The role of FUS gene variants in neurodegenerative diseases. *Nat Rev Neurol*. 2014; 10(6):337–48. <https://doi.org/10.1038/nrneurol.2014.78> PMID: [24840975](#)
36. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature*. 1993; 362(6415):59–62. <https://doi.org/10.1038/362059a0> PMID: [8446170](#)
37. Renton AE, Chiò A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. *Nat Neurosci*. 2013; 17(1):17–23. <https://doi.org/10.1038/nn.3584> PMID: [24369373](#)
38. Spisak K, Klimkowicz-Mrowiec A, Pera J, Dziedzic T, Aleksandra G, Slowik A. rs2070424 of the SOD1 gene is associated with risk of Alzheimer's disease. Vol. 48, *Neurologia i Neurochirurgia Polska*. 2014.
39. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. *Mov Disord*. 2008; 23(6):837–44. <https://doi.org/10.1002/mds.21956> PMID: [18307261](#)
40. Kurosinski P, Guggisberg M, Götz J. Alzheimer's and Parkinson's disease—overlapping or synergistic pathologies? *Trends Mol Med*. 2002; 8(1):3–5. PMID: [11796255](#)
41. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. *N Engl J Med*. 2003; 348(14):1356–64. <https://doi.org/10.1056/NEJM2003ra020003> PMID: [12672864](#)
42. Trinh J, Farrer M. Advances in the genetics of Parkinson disease. *Nat Rev Neurol*. 2013; 9(8):445–54. <https://doi.org/10.1038/nrneurol.2013.132> PMID: [23857047](#)
43. Moskvina V, Harold D, Russo G, Vedernikov A, Sharma M, Saad M, et al. Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk. *JAMA Neurol*. 2013; 70(10):1268–76. <https://doi.org/10.1001/jamaneurol.2013.448> PMID: [23921447](#)
44. Desikan RS, Schork AJ, Wang Y, Witoelar A, Sharma M, McEvoy LK, et al. Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. *Mol Psychiatry*. 2015; 20(12):1588–95. <https://doi.org/10.1038/mp.2015.6> PMID: [25687773](#)
45. Cruchaga C, Haller G, Chakraverty S, Mayo K, Vallania FLM, Mitra RD, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. *PLoS One*. 2012; 7(2):e31039. <https://doi.org/10.1371/journal.pone.0031039> PMID: [22312439](#)
46. Cruts M, van Duijn CM, Backhovens H, Van den Broeck M, Wehnert A, Serneels S, et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. *Hum Mol Genet*. 1998; 7(1):43–51. PMID: [9384602](#)
47. Ataka S, Tomiyama T, Takuma H, Yamashita T, Shimada H, Tsutada T, et al. A novel presenilin-1 mutation (Leu85Pro) in early-onset Alzheimer disease with spastic paraparesis. *Arch Neurol*. 2004; 61(11):1773–6. <https://doi.org/10.1001/archneur.61.11.1773> PMID: [15534188](#)
48. Lee JH, Kahn A, Cheng R, Reitz C, Vardarajan B, Lantigua R, et al. Disease-related mutations among Caribbean Hispanics with familial dementia. *Mol Genet genomic Med*. 2014; 2(5):430–7. <https://doi.org/10.1002/mgg3.85> PMID: [25333068](#)
49. Athan ES, Williamson J, Ciappa A, Santana V, Romas SN, Lee JH, et al. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. *JAMA*. 2001; 286(18):2257–63. PMID: [11710891](#)
50. Pérez-Tur J, Croxton R, Wright K, Philips H, Zehr C, Crook R, et al. A further presenilin 1 mutation in the exon 8 cluster in familial Alzheimer's disease. *Neurodegeneration*. 1996; 5(3):207–12. PMID: [8910898](#)

51. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science*. 1995; 269(5226):973–7. PMID: [7638622](#)
52. Guerreiro RJ, Baquero M, Blesa R, Boada M, Brás JM, Bullido MJ, et al. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. *Neurobiol Aging*. 2010; 31(5):725–31. <https://doi.org/10.1016/j.neurobiolaging.2008.06.012> PMID: [18667258](#)
53. Eckman CB, Mehta ND, Crook R, Perez-tur J, Prihar G, Pfeiffer E, et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). *Hum Mol Genet*. 1997; 6(12):2087–9. PMID: [9328472](#)
54. Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. *Science*. 1991; 254(5028):97–9. PMID: [1925564](#)
55. Coleman P, Kurlan R, Crook R, Werner J, Hardy J. A new presenilin Alzheimer's disease case confirms the helical alignment of pathogenic mutations in transmembrane domain 5. *Neurosci Lett*. 2004; 364(3):139–40. <https://doi.org/10.1016/j.neulet.2004.04.030> PMID: [15196662](#)
56. Raux G, Guyant-Maréchal L, Martin C, Bou J, Penet C, Brice A, et al. Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. *J Med Genet*. 2005; 42(10):793–5. <https://doi.org/10.1136/jmg.2005.033456> PMID: [16033913](#)
57. Bernardi L, Tomaino C, Anfossi M, Gallo M, Geracitano S, Costanzo A, et al. Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia. *Neurobiol Aging*. 2009; 30(11):1825–33. <https://doi.org/10.1016/j.neurobiolaging.2008.01.005> PMID: [18314228](#)
58. Aldudo J, Bullido MJ, Valdivieso F. DGGE method for the mutational analysis of the coding and proximal promoter regions of the Alzheimer's disease presenilin-1 gene: Two novel mutations. *Hum Mutat*. 1999; 14(5):433–9. [https://doi.org/10.1002/\(SICI\)1098-1004\(199911\)14:5<433::AID-HUMU10>3.0.CO;2-K](https://doi.org/10.1002/(SICI)1098-1004(199911)14:5<433::AID-HUMU10>3.0.CO;2-K) PMID: [10533070](#)
59. Piscopo P, Marcon G, Piras MR, Crestini A, Campeggi LM, Deiana E, et al. A novel PSEN2 mutation associated with a peculiar phenotype. *Neurology*. 2008; 70(17):1549–54. <https://doi.org/10.1212/01.wnl.0000310643.53587.87> PMID: [18427071](#)
60. Blauwendraat C, Wilke C, Jansen IE, Schulte C, Simón-Sánchez J, Metzger FG, et al. Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants. *Neurobiol Aging*. 2016 Jan; 37:208.e11–7.
61. Le Ber I, Camuzat A, Hannequin D, Pasquier F, Guedj E, Rovelet-Lecrux A, et al. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. *Brain*. 2008; 131(Pt 3):732–46. Available from: <http://brain.oxfordjournals.org/content/131/3/732.long> <https://doi.org/10.1093/brain/awn012> PMID: [18245784](#)
62. Bruni AC, Momeni P, Bernardi L, Tomaino C, Frangipane F, Elder J, et al. Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation. *Neurology*. 2007; 69(2):140–7. <https://doi.org/10.1212/01.wnl.0000265220.64396.b4> PMID: [17620546](#)
63. Huey ED, Grafman J, Wassermann EM, Pietrini P, Tierney MC, Ghetti B, et al. Characteristics of frontotemporal dementia patients with a *Progranulin* mutation. *Ann Neurol*. 2006; 60(3):374–80. <https://doi.org/10.1002/ana.20969> PMID: [16983677](#)
64. Cruchaga C, Fernández-Seara MA, Seijo-Martínez M, Samaranch L, Lorenzo E, Hinrichs A, et al. Cortical atrophy and language network reorganization associated with a novel progranulin mutation. *Cereb Cortex*. 2009; 19(8):1751–60. <https://doi.org/10.1093/cercor/bhn202> PMID: [19020205](#)
65. Murrell JR, Spillantini MG, Zolo P, Guazzelli M, Smith MJ, Hasegawa M, et al. Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits. *J Neuro-pathol Exp Neurol*. 1999 Dec; 58(12):1207–26. PMID: [10604746](#)
66. Rademakers R, Dermaut B, Peeters K, Cruts M, Heutink P, Goate A, et al. Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe. *Hum Mutat*. 2003 Nov; 22(5):409–11. <https://doi.org/10.1002/humu.10269> PMID: [14517953](#)
67. Corrado L, Ratti A, Gellera C, Buratti E, Castellotti B, Carlomagno Y, et al. High frequency of *TARDBP* gene mutations in Italian patients with amyotrophic lateral sclerosis. *Hum Mutat*. 2009; 30(4):688–94. <https://doi.org/10.1002/humu.20950> PMID: [19224587](#)
68. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. *TARDBP* mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. *Nat Genet*. 2008; 40(5):572–4. <https://doi.org/10.1038/ng.132> PMID: [18372902](#)
69. Watts G, Wymer J, Kovach M, Mehta SG, Mumm S, Darvish D, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. *Nat Genet*. 36(4):377–81. <https://doi.org/10.1038/ng1332> PMID: [15034582](#)

70. Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. *Hum Mutat.* 2012; 33(9):1340–4. <https://doi.org/10.1002/humu.22117> PMID: 22581678
71. Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. *Lancet.* 2005 Jan; 365(9457):412–5 [https://doi.org/10.1016/S0140-6736\(05\)17829-5](https://doi.org/10.1016/S0140-6736(05)17829-5) PMID: 15680456
72. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology. *Neuron.* 2004; 44(4):601–7 <https://doi.org/10.1016/j.neuron.2004.11.005> PMID: 15541309
73. Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, et al. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. *BMC Med.* 2008; 6(1):32.
74. Nisipeanu P, Inzelberg R, Abo Mouch S, Carasso RL, Blumen SC, Zhang J, et al. Parkin gene causing benign autosomal recessive juvenile parkinsonism. *Neurology.* 2001; 56(11):1573–5. PMID: 11402119
75. Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D, et al. Lewy bodies and parkinsonism in families with parkin mutations. *Ann Neurol.* 2001; 50(3):293–300. PMID: 11558785
76. Hedrich K, Marder K, Harris J, Kann M, Lynch T, Meija-Santana H, et al. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. *Neurology.* 2002; 58(8):1239–46. PMID: 11971093
77. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. *Neurology.* 2003; 60(5):796–801 PMID: 12629236
78. Macedo MG, Verbaan D, Fang Y, van Rooden SM, Visser M, Anar B, et al. Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. *Mov Disord.* 2009; 24(2):196–203. <https://doi.org/10.1002/mds.22287> PMID: 18973254
79. Wang M, Hattori N, Matsumine H, Kobayashi T, Yoshino H, Morioka A, et al. Polymorphism in the parkin gene in sporadic Parkinson's disease. *Ann Neurol.* 1999; 45(5):655–8. PMID: 10319889
80. Harms M, Benitez BA, Cairns N, Cooper B, Cooper P, Mayo K, et al. C9orf72 Hexanucleotide Repeat Expansions in Clinical Alzheimer Disease. *JAMA Neurol.* 2013 Jun 1; 70(6):736. <https://doi.org/10.1001/2013.jamaneurol.537> PMID: 23588422
81. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. *J Neuropathol Exp Neurol.* 2012; 71(4):266–73. <https://doi.org/10.1097/NEN.0b013e31824b211b> PMID: 22437338
82. Marcon G, Di Fede G, Giaccone G, Rossi G, Giovagnoli AR, Maccagnano E, et al. A novel Italian presenilin 2 gene mutation with prevalent behavioral phenotype. *J Alzheimers Dis.* 2009; 16(3):509–11. <https://doi.org/10.3233/JAD-2009-0986> PMID: 19276543
83. Rademakers R, Baker M, Gass J, Adamson J, Huey ED, Momeni P, et al. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: an international initiative. *Lancet Neurol.* 2007; 6(10):857–68. [https://doi.org/10.1016/S1474-4422\(07\)70221-1](https://doi.org/10.1016/S1474-4422(07)70221-1) PMID: 17826340
84. Keogh MJ, Wei W, Wilson I, Coxhead J, Ryan S, Rollinson S, et al. Genetic compendium of 1511 human brains available through the UK Medical Research Council Brain Banks Network Resource. *Genome Res.* 2017; 27(1):165–173 <https://doi.org/10.1101/gr.210609.116> PMID: 28003435
85. Ujii S, Hatano T, Kubo S, Imai S, Sato S, Uchihara T, et al. LRRK2 I2020T mutation is associated with tau pathology. *Parkinsonism Relat Disord.* 2012; 18(7):819–23. <https://doi.org/10.1016/j.parkreldis.2012.03.024> PMID: 22525366
86. Zhao Y, Ho P, Yih Y, Chen C, Lee WL, Tan EK. LRRK2 variant associated with Alzheimer's disease. *Neurobiol Aging.* 2011; 32(11):1990–3. <https://doi.org/10.1016/j.neurobiolaging.2009.11.019> PMID: 20018409
87. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. *Neurology.* 2005; 65(12):1863–72. <https://doi.org/10.1212/01.wnl.0000187889.17253.b1> PMID: 16237129
88. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? *Brain.* 2011; 134(5):1493–505.
89. Guerreiro R, Escott-Price V, Darwent L, Parkkinen L, Ansorge O, Hernandez DG, et al. Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. *Neurobiol Aging.* 2016; 38:214.e7–214.e10.

90. Hatano Y, Li Y, Sato K, Asakawa S, Yamamura Y, Tomiyama H, et al. Novel PINK1 mutations in early-onset parkinsonism. *Annals of Neurol.* 2004; 53(3):424–7.
91. Day GS, Musiek ES, Roe CM, Norton J, Goate AM, Cruchaga C, et al. Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease. *JAMA Neurol.* 2016; 73(9):1125. <https://doi.org/10.1001/jamaneurol.2016.1236> PMID: 27454811
92. Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, et al. Coding variants in TREM2 increase risk for Alzheimer's disease. *Hum Mol Genet.* 2014; 23(21):5838–46. <https://doi.org/10.1093/hmg/ddu277> PMID: 24899047
93. Cruchaga C, Karch CM, Jin SC, Benitez BA, Cai Y, Guerreiro R, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. *Nature.* 2014; 505(7484):550–4. <https://doi.org/10.1038/nature12825> PMID: 24336208
94. Del-Aguila JL, Koboldt DC, Black K, Chasse R, Norton J, Wilson RK, et al. Alzheimer's disease: rare variants with large effect sizes. *Curr Opin Genet Dev.* 2015 Aug 22 [cited 2015 Sep 2]; 33:49–55. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26311074> PMID: 26311074
95. Fernández MV, Black K, Carrell D, Saef B, Budde J, Deming Y, et al. SORL1 variants across Alzheimer's disease European American cohorts. *Eur J Hum Genet.* 2016; 24(12):1828–1830. *Eur J Hum Genet.* 2016; <https://doi.org/10.1038/ejhg.2016.122> PMID: 27650968
96. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology.* 1984; 34(7):939–44. PMID: 6610841
97. Berg L, McKeel DW, Miller JP, Storandt M, Rubin EH, Morris JC, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. *Arch Neurol.* 1998; 55(3):326–35. PMID: 9520006
98. Coats M, Morris JC. Antecedent biomarkers of Alzheimer's disease: the adult children study. *J Geriatr Psychiatry Neurol.* 2005; 18(4):242–4. <https://doi.org/10.1177/0891988705281881> PMID: 16306247
99. Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, Cheng R, et al. Genome-Wide Association of Familial Late-Onset Alzheimer's Disease Replicates BIN1 and CLU and Nominates CUGBP2 in Interaction with APOE. Myers AJ, editor. *PLoS Genet.* 2011; 7(2):e1001308. <https://doi.org/10.1371/journal.pgen.1001308> PMID: 21379329
100. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly (Austin)* 2012; 6(2):80–92.
101. Harms MB, Cady J, Zaidman C, Cooper P, Bali T, Allred P, et al. Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis. *Neurobiol Aging.* 2013; 34(9):2234.e13–9.
102. Harms MB, Neumann D, Benitez BA, Cooper B, Carrell D, Racette BA, et al. Parkinson disease is not associated with C9ORF72 repeat expansions. *Neurobiol Aging.* 2013; 34(5):1519.e1–1519.e2.
103. Lin MK, Farrer MJ, Lau L de, Breteler M, Fahn S, Benabid A, et al. Genetics and genomics of Parkinson's disease. *Genome Med.* 2014; 6(6):48 <https://doi.org/10.1186/gm566> PMID: 25061481
104. Hernandez DG, Reed X, Singleton AB. Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. *J Neurochem.* 2016; 139:59–74. <https://doi.org/10.1111/jnc.13593> PMID: 27090875
105. Zhan X, Hu Y, Li B, Abecasis GR, Liu DJ. RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data: Table 1. *Bioinformatics.* 2016; 32(9):1423–6. <https://doi.org/10.1093/bioinformatics/btw079> PMID: 27153000
106. Walsh R, Thomson KL, Ware JS, Funke BH, Woodley J, McGuire KJ, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. *Genet Med.* 2017; 19(2):192–203. <https://doi.org/10.1038/gim.2016.90> PMID: 27532257
107. Roberts AM, Ware JS, Herman DS, Schafer S, Baksi J, Bick AG, et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. *Sci Transl Med.* 2015; 7(270):270ra6. <https://doi.org/10.1126/scitranslmed.3010134> PMID: 25589632
108. Lek M, Karczewski KJ, Minikel E V., Samocha KE, Banks E, Fennell, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature.* 2016; 536(7616):285–91. <https://doi.org/10.1038/nature19057> PMID: 27535533
109. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.